Center for Inflammatory Bowel Disease
The UCLA Inflammatory Bowel Disease Research Center, established in 2007, focuses on multiple aspects of the pathophysiology, therapy, and diagnosis of IBD with some of the funding from the National Institutes of Health (NIH), the American College of Gastroenterology (AGA), and the Crohn's & Colitis Foundation. Their discoveries are not only helping to unravel the mysteries driving IBD pathogenesis at the molecular and cellular levels, but they are also providing targets for new therapeutic approaches — some of which are currently under investigation.
In addition, our experts integrate these latest discoveries into the care of our patients.
Research collaborations
Corrona Inflammatory Bowel Disease Registry
The objective of the Corrona Inflammatory Bowel Diseases (IBD) Registry is to create a national cohort of patients with Crohn's disease (CD), ulcerative colitis (UC) and indeterminate colitis (IC). Data collected will be used to better characterize the natural history of the disease and to extensively evaluate the effectiveness and safety of medications approved for the treatment of IBD. Corrona IBD Registry | Enroll in the Registry
Clinical trials
A primary motivation in our efforts to perform biomedical and clinical research has been to advance knowledge that can be used to improve the care we deliver and the quality of our patients’ lives.
View open trials and studies in the Berkeley Limketkai Lab for IBD and nutrition and others related to IBD.
Jacobs Laboratory
Our work in the microbiome realm includes a group headed by Jonathan P. Jacobs, MD, PhD, that is investigating how the intestinal microbiome contributes to IBD development. Jacobs Laboratory
Koon Laboratory
Hon Wai Koon, PhD, is a basic science research faculty of UCLA Center for Inflammatory Bowel Diseases. He leads a research team to discover novel diagnostic biomarkers for indicating IBD disease activity and risk of intestinal strictures. His team also finds new targets in IBD, C. difficile infection, obesity, diabetes and colon cancer for developing new therapies. His laboratory has a biobank of clinical samples and data, a collection of animal models with various diseases, and diseased primary cell, organoid and fresh tissue platforms for research. Dr. Koon’s laboratory is also a center for multidisciplinary research training and collaborations. Koon Laboratory
Limketkai Laboratory
Berkeley Limketkai, MD, PhD, leads a clinical/translational research laboratory whose mission is the generation, experimentation, and application of knowledge that can help shape and improve future care of our patients. Our key research themes -- individually and in combination -- include the domains of inflammatory bowel diseases (IBD), nutrition and biomedical innovation. Limketkai Laboratory
G. Oppenheimer Center for Neurobiology of Stress and Resilience
Emeran A. Mayer, MD, and his colleagues are conducting pioneering studies exploring the interactions between IBD and the nervous system, amid mounting interest in the role of brain alterations in IBD pathogenesis. G. Oppenheimer Center for Neurobiology of Stress and Resilience
Goodman-Luskin Microbiome Center
A wide-range of human and preclinical studies are taking place to identify gut microbes and their metabolites that drive the development and progression of IBD and characterize their interactions with the intestinal immune system. Specific areas of focus include understanding microbial changes that preceded the onset of IBD, investigating dietary effects on the IBD-associated microbiome and intestinal inflammation, and defining brain-gut pathways in IBD that mediate the link between stress and disease flares. Goodman-Luskin Microbiome Center